Therapeutic directions for Parkinson's disease.
Therapeutic directions for Parkinson's disease.
复制标题
DOI：
10.1002/mds.22790
复制
发表时间：
2010
影响因子：
8.6
通讯作者：
Shoulson, Ira
中科院分区：
文献类型：
--
作者：
Shoulson, Ira
对帕金森病（PD）疾病缓解疗法和治愈方法的关注提高了人们对巨大飞跃的期望，并掩盖了缓慢实现的增量成果。 DATATOP 和 PRECEPT 等大型多中心临床试验不断产生与临床护理和实验治疗相关的新知识。在这些临床试验中，循环尿酸与帕金森病的发生和进展之间的关系在很大程度上是不可预见的。干预阶段结束后对临床试验队列的系统随访提供了附加价值，可以继续提供有关自然史、状态和性状生物标志物以及基因型-表型关系的信息。这些努力通过数据挖掘、公开报告以及及时共享数据和生物样本得到加强。 © 2010 运动障碍协会
The focus on disease‐modifying treatments and cures for Parkinson's disease (PD) has raised expectations for quantum leaps and overshadowed incremental gains that have been slowly achieved. Large multi‐center clinical trials such as DATATOP and PRECEPT keep on generating new knowledge that is relevant to clinical care as well as experimental therapeutics. The largely unforeseen relationship between circulating uric acid and the occurrence and progression of PD was developed and confirmed in these clinical trials. Systematic follow‐up of clinical trial cohorts after conclusion of the interventional phase provides added value that continues to inform about natural history, state and trait biomarkers, and genotype‐phenotype relationships. These efforts are enhanced by data mining, public reporting, and timely sharing of data and biological samples. © 2010 Movement Disorder Society
登录
查看更多内容
影响因子：
--
作者：
Schwarzschild, Michael A.;Schwid, Steven R.;Ascherio, Alberto
通讯作者：
Ascherio, Alberto
影响因子：
11.2
作者：
Shoulson, I
通讯作者：
Shoulson, I
影响因子：
11.2
作者：
SEIBYL, JP;MAREK, KL;INNIS, RB
通讯作者：
INNIS, RB
影响因子：
9.9
作者：
Shoulson, Ira;Schwid, Steven;Seibyl, John
通讯作者：
Seibyl, John
影响因子：
48
作者：
Olanow, C. Warren;Schapira, Anthony H. V.;Hubble, Jean
通讯作者：
Hubble, Jean